The contact centers for pharma market size is expected to see rapid growth in the next few years. It will grow to $5.1 billion in 2030 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to the increasing deployment of AI-enabled conversational agents and virtual assistants, expansion of scalable cloud-based pharmaceutical contact center infrastructure, rising focus on patient-centric care and engagement strategies, growth in real-time pharmacovigilance and safety monitoring requirements, and greater integration of advanced analytics into pharmaceutical communication workflows. Major trends in the forecast period include AI-powered omnichannel contact center automation and intelligent routing systems in pharmaceuticals, cloud-based patient engagement and support platforms, integrated pharmacovigilance reporting and real-time safety monitoring systems, data-driven personalization of pharmaceutical customer experiences, and increasing adoption of virtual medical information and remote patient support services.
The expansion of clinical trials is expected to propel the growth of the contact centers for pharma market going forward. Clinical trials refer to carefully designed research studies conducted on human participants to evaluate the safety, effectiveness, and side effects of new medical treatments, drugs, or medical devices before they are approved for public use. Clinical trials are growing due to increasing demand for new and more effective treatments for chronic and complex diseases, along with rising investment from pharmaceutical and biotechnology companies in drug development and regulatory approvals. Contact centers for pharma enhance clinical trials by managing communication between researchers, participants, and healthcare providers, ensuring timely coordination, patient engagement, query resolution, and accurate information flow throughout all phases of the trial process to improve efficiency and compliance. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, highlighted that the number of pharmaceutical industry trials launched in the UK increased for the second consecutive year, rising from 411 in 2022 to 426 in 2023. Therefore, the expansion of clinical trials is driving the growth of the contact centers for pharma market.
The growth of specialty and biologic drugs is expected to propel the growth of the contact centers for pharma market going forward. Specialty and biologic drugs refer to advanced, high-complexity therapies derived from living organisms and used to treat chronic, rare, or complex diseases. Specialty and biologic drugs are rising due to rapid advances in biotechnology and an increasing global burden of chronic and complex diseases, which require more targeted and effective treatment options. Contact centers for pharma enable effective management of specialty and biologic drugs through continuous patient engagement, adherence monitoring, education on treatment regimens, coordination between healthcare providers and patients, and timely resolution of therapy-related queries, ensuring proper usage and improved treatment outcomes. For instance, in February 2025, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, the 2023 WHO Essential Medicines List includes 81 biologic therapies, representing over 15% of all listed medicines. Therefore, the growth of specialty and biologic drugs is driving the growth of the contact centers for pharma market.
The growth of patient support programs is expected to propel the growth of the contact centers for pharma market going forward. Patient support programs are structured healthcare services provided by pharmaceutical companies to assist patients in accessing, adhering to, and managing prescribed therapies. Patient support programs are rising due to the increasing complexity of therapies, which makes it difficult for patients to manage medication schedules, side effects, and long-term treatment requirements without structured guidance and ongoing support. Patient support programs enhance contact centers for pharma by creating a continuous communication system where patients receive real-time assistance, adherence reminders, and treatment guidance through centralized channels, which increases patient engagement and improves the efficiency and demand for pharma-focused contact center services. For instance, in August 2024, according to the Health Resources and Services Administration (HRSA), a US-based government agency, HRSA-funded health centers served over 31 million patients in 2023, with the majority being low-income individuals and vulnerable populations. Therefore, the growth of patient support programs is driving the growth of the contact centers for pharma market.
Major companies operating in the contact centers for pharma market are Accenture plc, Capgemini SE, Cognizant Technology Solutions Corporation, IQVIA Holdings Inc., Infosys BPM Limited, Wipro Limited, HCL Technologies Limited, Teleperformance SE, Concentrix Corporation, Veeva Systems Inc., ICON Public Limited Company, Syneos Health Inc., Genpact Limited, Foundever Group S.A., Genesys Telecommunications Laboratories Inc., NICE Ltd., Conduent Incorporated, ExlService Holdings Inc., WNS (Holdings) Limited, TTEC Holdings Inc., RingCentral Inc., Inizio Engage, EVERSANA, ProPharma Group, Talkdesk Inc., Ubiquity Global Services Inc., Fusion CX Limited, Qualfon Group, IntelePeer Cloud Communications LLC, PharmaCentra LLC.
North America was the dominant region in the contact centers for pharma market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in contact centers for pharma report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the contact centers for pharma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The contact centers for pharma market consists of revenues earned by entities by providing services such as multi-channel customer support, medical information services, patient engagement programs, call handling for drug safety reporting, omnichannel communication management, CRM integration, data capture and analytics, and outsourcing of contact center operations for pharmaceutical companies. The market value includes the value of related services and technology platforms used to deliver these services. Only services exchanged between entities or provided to end users are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The contact centers for pharma market research report is one of a series of new reports that provides contact centers for pharma market statistics, including contact centers for pharma industry global market size, regional shares, competitors with a contact centers for pharma market share, detailed contact centers for pharma market segments, market trends and opportunities, and any further data you may need to thrive in the contact centers for pharma industry. This contact centers for pharma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
Table of Contents
Executive Summary
Contact Centers For Pharma Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses contact centers for pharma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for contact centers for pharma? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The contact centers for pharma market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Component: Software; Services2) By Function: Customer Support; Medical Information; Adverse Event Reporting; Patient Adherence; Sales Support; Other Function
3) By Enterprise Size: Large Enterprises; Small And Medium Enterprises
4) By Deployment Mode: On Premises; Cloud-Based
5) By End User: Pharmaceutical Companies; Contract Research Organizations; Healthcare Providers; Other End Users
Subsegments:
1) By Software: Omnichannel Contact Center Software; Customer Relationship Management Integration Software; Interactive Voice Response Software; Workforce Management Software; Analytics And Reporting Software2) By Services: Implementation And Integration Services; Consulting And Advisory Services; Managed Contact Center Services; Training And Support Services; Maintenance And Optimization Services
Companies Mentioned: Accenture plc; Capgemini SE; Cognizant Technology Solutions Corporation; IQVIA Holdings Inc.; Infosys BPM Limited; Wipro Limited; HCL Technologies Limited; Teleperformance SE; Concentrix Corporation; Veeva Systems Inc.; ICON Public Limited Company; Syneos Health Inc.; Genpact Limited; Foundever Group S.A.; Genesys Telecommunications Laboratories Inc.; NICE Ltd.; Conduent Incorporated; ExlService Holdings Inc.; WNS (Holdings) Limited; TTEC Holdings Inc.; RingCentral Inc.; Inizio Engage; EVERSANA; ProPharma Group; Talkdesk Inc.; Ubiquity Global Services Inc.; Fusion CX Limited; Qualfon Group; IntelePeer Cloud Communications LLC; PharmaCentra LLC
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
- Accenture plc
- Capgemini SE
- Cognizant Technology Solutions Corporation
- IQVIA Holdings Inc.
- Infosys BPM Limited
- Wipro Limited
- HCL Technologies Limited
- Teleperformance SE
- Concentrix Corporation
- Veeva Systems Inc.
- ICON Public Limited Company
- Syneos Health Inc.
- Genpact Limited
- Foundever Group S.A.
- Genesys Telecommunications Laboratories Inc.
- NICE Ltd.
- Conduent Incorporated
- ExlService Holdings Inc.
- WNS (Holdings) Limited
- TTEC Holdings Inc.
- RingCentral Inc.
- Inizio Engage
- EVERSANA
- ProPharma Group
- Talkdesk Inc.
- Ubiquity Global Services Inc.
- Fusion CX Limited
- Qualfon Group
- IntelePeer Cloud Communications LLC
- PharmaCentra LLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | July 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.29 Billion |
| Forecasted Market Value ( USD | $ 5.1 Billion |
| Compound Annual Growth Rate | 11.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |


